Cargando…
Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties?
BACKGROUND: After focused high dose radiotherapy of brain metastases, differentiation between tumor recurrence and radiation-induced lesions by conventional MRI is challenging. This study investigates the usefulness of dynamic O-(2-(18)F-Fluoroethyl)-L-Tyrosine positron emission tomography ((18)F-FE...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073742/ https://www.ncbi.nlm.nih.gov/pubmed/27769279 http://dx.doi.org/10.1186/s13014-016-0713-8 |
_version_ | 1782461624954650624 |
---|---|
author | Romagna, Alexander Unterrainer, Marcus Schmid-Tannwald, Christine Brendel, Matthias Tonn, Jörg-Christian Nachbichler, Silke Birgit Muacevic, Alexander Bartenstein, Peter Kreth, Friedrich-Wilhelm Albert, Nathalie Lisa |
author_facet | Romagna, Alexander Unterrainer, Marcus Schmid-Tannwald, Christine Brendel, Matthias Tonn, Jörg-Christian Nachbichler, Silke Birgit Muacevic, Alexander Bartenstein, Peter Kreth, Friedrich-Wilhelm Albert, Nathalie Lisa |
author_sort | Romagna, Alexander |
collection | PubMed |
description | BACKGROUND: After focused high dose radiotherapy of brain metastases, differentiation between tumor recurrence and radiation-induced lesions by conventional MRI is challenging. This study investigates the usefulness of dynamic O-(2-(18)F-Fluoroethyl)-L-Tyrosine positron emission tomography ((18)F-FET PET) in patients with MRI-based suspicion of tumor recurrence after focused high dose radiotherapy of brain metastases. METHODS: Twenty-two patients with 34 brain metastases (median age 61.9 years) were included. Due to follow-up scan evaluations after repeated treatment in a subset of patients, a total of 50 lesions with MRI-based suspicion of tumor recurrence after focused high dose radiotherapy could be evaluated. (18)F-FET PET analysis included the assessment of maximum and mean tumor-to-background ratio (TBR(max) and TBR(mean)) and analysis of time-activity-curves (TAC; increasing vs. decreasing) including minimal time-to-peak (TTP(min)). PET parameters were correlated with histological findings and radiological-clinical follow-up evaluation. RESULTS: Tumor recurrence was found in 21/50 cases (15/21 verified by histology, 6/21 by radiological-clinical follow-up) and radiation-induced changes in 29/50 cases (5/29 verified by histology, 24/29 by radiological-clinical follow-up). Median clinical-radiological follow-up was 28.3 months (range 4.2–99.1 months). (18)F-FET uptake was higher in tumor recurrence compared to radiation-induced changes (TBR(max) 2.9 vs. 2.0, p < 0.001; TBR(mean) 2.2 vs. 1.7, p < 0.001). Receiver-operating-characteristic (ROC) curve analysis revealed optimal cut-off values of 2.15 for TBR(max) and 1.95 for TBR(mean) (sensitivity 86 %, specificity 79 %). Increasing TACs and long TTP(min) were associated with radiation-induced changes, decreasing TACs with tumor recurrence (p = 0.01). By combination of TBR and TACs, sensitivity and specificity could be increased to 93 and 84 %. CONCLUSIONS: In patients with MRI-suspected tumor recurrence after focused high dose radiotherapy, (18)F-FET PET has a high sensitivity and specificity for the differentiation of vital tumor tissue and radiation-induced lesions. |
format | Online Article Text |
id | pubmed-5073742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50737422016-10-24 Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? Romagna, Alexander Unterrainer, Marcus Schmid-Tannwald, Christine Brendel, Matthias Tonn, Jörg-Christian Nachbichler, Silke Birgit Muacevic, Alexander Bartenstein, Peter Kreth, Friedrich-Wilhelm Albert, Nathalie Lisa Radiat Oncol Research BACKGROUND: After focused high dose radiotherapy of brain metastases, differentiation between tumor recurrence and radiation-induced lesions by conventional MRI is challenging. This study investigates the usefulness of dynamic O-(2-(18)F-Fluoroethyl)-L-Tyrosine positron emission tomography ((18)F-FET PET) in patients with MRI-based suspicion of tumor recurrence after focused high dose radiotherapy of brain metastases. METHODS: Twenty-two patients with 34 brain metastases (median age 61.9 years) were included. Due to follow-up scan evaluations after repeated treatment in a subset of patients, a total of 50 lesions with MRI-based suspicion of tumor recurrence after focused high dose radiotherapy could be evaluated. (18)F-FET PET analysis included the assessment of maximum and mean tumor-to-background ratio (TBR(max) and TBR(mean)) and analysis of time-activity-curves (TAC; increasing vs. decreasing) including minimal time-to-peak (TTP(min)). PET parameters were correlated with histological findings and radiological-clinical follow-up evaluation. RESULTS: Tumor recurrence was found in 21/50 cases (15/21 verified by histology, 6/21 by radiological-clinical follow-up) and radiation-induced changes in 29/50 cases (5/29 verified by histology, 24/29 by radiological-clinical follow-up). Median clinical-radiological follow-up was 28.3 months (range 4.2–99.1 months). (18)F-FET uptake was higher in tumor recurrence compared to radiation-induced changes (TBR(max) 2.9 vs. 2.0, p < 0.001; TBR(mean) 2.2 vs. 1.7, p < 0.001). Receiver-operating-characteristic (ROC) curve analysis revealed optimal cut-off values of 2.15 for TBR(max) and 1.95 for TBR(mean) (sensitivity 86 %, specificity 79 %). Increasing TACs and long TTP(min) were associated with radiation-induced changes, decreasing TACs with tumor recurrence (p = 0.01). By combination of TBR and TACs, sensitivity and specificity could be increased to 93 and 84 %. CONCLUSIONS: In patients with MRI-suspected tumor recurrence after focused high dose radiotherapy, (18)F-FET PET has a high sensitivity and specificity for the differentiation of vital tumor tissue and radiation-induced lesions. BioMed Central 2016-10-21 /pmc/articles/PMC5073742/ /pubmed/27769279 http://dx.doi.org/10.1186/s13014-016-0713-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Romagna, Alexander Unterrainer, Marcus Schmid-Tannwald, Christine Brendel, Matthias Tonn, Jörg-Christian Nachbichler, Silke Birgit Muacevic, Alexander Bartenstein, Peter Kreth, Friedrich-Wilhelm Albert, Nathalie Lisa Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title_full | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title_fullStr | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title_full_unstemmed | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title_short | Suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)F]FET- PET overcome diagnostic uncertainties? |
title_sort | suspected recurrence of brain metastases after focused high dose radiotherapy: can [(18)f]fet- pet overcome diagnostic uncertainties? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073742/ https://www.ncbi.nlm.nih.gov/pubmed/27769279 http://dx.doi.org/10.1186/s13014-016-0713-8 |
work_keys_str_mv | AT romagnaalexander suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT unterrainermarcus suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT schmidtannwaldchristine suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT brendelmatthias suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT tonnjorgchristian suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT nachbichlersilkebirgit suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT muacevicalexander suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT bartensteinpeter suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT krethfriedrichwilhelm suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties AT albertnathalielisa suspectedrecurrenceofbrainmetastasesafterfocusedhighdoseradiotherapycan18ffetpetovercomediagnosticuncertainties |